# US 2014/0273061 A1 · Reagents, Systems and Methods for Analyzing Erythrocytes and Platelets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0273061 A1
- Document ID: US20140273061A1
- Status: Published application
- Kind: A1
- Application number: 14/137,392
- Filed: 2013-12-20
- Published: 2014-09-18
- Earliest claimed: 2013-03-12
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Jiong Wu; Ji Lin
- Web page: https://patentgrep.com/patent/US20140273061A1

## CPC

- G01N 33/56972: {White blood cells}
- G01N 15/1434: Optical arrangements
- G01N 15/1459: {the analysis being performed on a sample stream}
- G01N 21/47: Scattering, i.e. diffuse reflection (G01N21/25, G01N21/41 take precedence {G01N21/55 takes precedence})
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- G01N 15/0205: by optical means
- G01N 2015/012: {Red blood cells}
- G01N 2015/014: {Reticulocytes}
- G01N 2015/018: {Platelets}
- G01N 2015/0277: {Average size only}
- G01N 2015/1006: {for cytology}
- G01N 2015/1477: {Multiparameters}
- G01N 2015/1493: {Particle size}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Aspects of the invention include hematology analysis reagents, systems and methods that can be used to preserve blood cell morphology and integrity as well as provide sample integrity and optical clarity to facilitate optical analysis of blood samples. In some embodiments, the reagents include a non-phosphate organic buffer and a sphering surfactant. The pH and osmolality of the reagents may be adjusted to desired ranges. In addition, the reagents can be simply diluted with de-ionized water prior to use.

## Claims

### Claim 1

A system for conducting an optical MCV analysis on a sample of whole blood, the system comprising:
(a) a hematology analyzer, the hematology analyzer comprising:
an excitation source positioned to excite particles within the blood sample;
a plurality of detectors including (1) an axial light loss detector positioned to measure axial light loss from the excited blood sample, (2) an intermediate angle scatter detector positioned to measure intermediate angle scatters from the excited blood sample, (3) a polarized side scatter detector positioned to measure large angle polarized side scatters from the excited blood sample, (4) a depolarized side scatter detector positioned to measure large angle depolarized side scatters from the excited blood sample; and
a processor configured to:
(I) receive the measurements of (1) axial light loss, (2) intermediate angle scatters, (3) large angle polarized side scatters, (4) large angle depolarized side scatters, and
(II) perform an MCV analysis of the blood sample, based on a plurality of data received from the detectors; and
(b) a hematology reagent comprising:
a non-phosphate organic buffer;
a sphering surfactant; and
an osmolality adjustment component,
wherein the hematology reagent has sufficient optical clarity to facilitate optical analysis of the sample.

### Claim 2 (depends on 1)

The system according to claim 1, wherein the non-phosphate organic buffer is MES, MOPS, HEPES, or imidazole.

### Claim 3 (depends on 1)

The system according to claim 1, wherein the concentration of the non-phosphate organic buffer in the reagent is at least about 0.5%.

### Claim 4 (depends on 1)

The system according to claim 1, wherein the concentration of the non-phosphate organic buffer in the reagent ranges from about 0.5% up to about 20%.

### Claim 5 (depends on 1)

The system according to claim 1, wherein the concentration of the non-phosphate organic buffer in the reagent is at least about 50 mM.

### Claim 6 (depends on 1)

The system according to claim 1, wherein the concentration of the non-phosphate organic buffer in the reagent ranges from about 50 up to about 1,500 mM.

### Claim 7 (depends on 1)

The system according to claim 1, wherein the sphering surfactant is maltoside.

### Claim 8 (depends on 1)

The system according to claim 1, wherein the concentration of the sphering surfactant is at least about 0.0002%.

### Claim 9 (depends on 1)

The system according to claim 1, wherein the concentration of the sphering surfactant ranges from about 0.0002% up to about 2.0%.

### Claim 10 (depends on 1)

The system according to claim 1, wherein the concentration of the sphering surfactant is at least about 5 mg/L.

### Claim 11 (depends on 1)

The system according to claim 1, wherein the concentration of the sphering surfactant ranges from about 5 up to about 1,000 mg/L.

### Claim 12 (depends on 1)

The system according to claim 1, wherein the osmolality adjustment component is sodium chloride, potassium chloride or a mixture thereof.

### Claim 13 (depends on 1)

The system according to claim 1, wherein the concentration of the osmolality adjustment component is at least about 0.25%.

### Claim 14 (depends on 1)

The system according to claim 1, wherein the concentration of the osmolality adjustment component ranges from about 0.25% up to about 25%.

### Claim 15 (depends on 1)

The system according to claim 1, wherein the reagent further comprises an antimicrobial agent.

### Claim 16 (depends on 15)

The system according to claim 15, wherein the concentration of the antimicrobial agent is at least about 0.2%.

### Claim 17 (depends on 15)

The system according to claim 15, wherein the concentration of the antimicrobial agent ranges from about 0.02% up to about 0.1%.

### Claim 18 (depends on 1)

The system according to claim 1, wherein the pH of the reagent ranges from about 6.0 up to about 8.0 pH units.

### Claim 19 (depends on 1)

The system according to claim 1, wherein the osmolality of a 1× concentration solution of the reagent ranges from about 250 up to about 350 mOsm.

### Claim 20 (depends on 1)

The system according to claim 1, wherein the plurality of detectors include one or more photomultiplier tubes and/or avalanche photo diodes (APDs).

### Claim 21 (depends on 1)

The system according to claim 1, wherein the excitation source is a laser.

### Claim 22 (depends on 1)

The system according to claim 1, further comprising a subsystem for diluting the reagent.

### Claim 23 (depends on 22)

The system according to claim 22, wherein the subsystem is configured to mix the diluted reagent with the blood sample.

### Claim 24 (depends on 23)

The system according to claim 23, wherein the subsystem is configured to incubate the blood sample with the reagent for a period of time ranging from about 1 to about 30 seconds.

### Claim 25 (depends on 23)

The system according to claim 23, wherein the subsystem is configured to incubate the blood sample with the diluted reagent at a temperature ranging from about 15° C. to about 50° C.

### Claim 26 (depends on 23)

The system according to claim 23, wherein the subsystem is configured to incubate the blood sample with the diluted reagent at ambient temperature.

### Claim 27

A method of performing an optical mean corpuscular volume (MCV) analysis with an automated hematology analyzer, the method comprising:
(a) diluting a sample of whole blood with a 1× concentration working solution of a hematology analysis reagent, wherein the hematology analysis reagent comprises:
a non-phosphate organic buffer;
a sphering surfactant; and
an osmolality adjustment component,
wherein the hematology reagent has sufficient optical clarity to facilitate optical analysis of the sample;
(b) delivering the incubated sample from step (a) to a flow cell of the hematology analyzer;
(c) exciting the incubated sample from step (b) with an excitation source as the sample traverses the flow cell;
(d) collecting a plurality of light scatter signals from the excited sample; and
(e) analyzing the signals collected in step (d) to determine the MCV of the sample.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the non-phosphate organic buffer is MES, MOPS, HEPES, or imidazole.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the concentration of the non-phosphate organic buffer in the reagent ranges from about 0.5% up to about 20%.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the concentration of the non-phosphate organic buffer in the reagent ranges from about 50 up to about 1,500 mM.

### Claim 31 (depends on 27)

The method according to claim 27, wherein the sphering surfactant is maltoside.

### Claim 32 (depends on 27)

The method according to claim 27, wherein the concentration of the sphering surfactant ranges from about 0.0002% up to about 2.0%.

### Claim 33 (depends on 27)

The method according to claim 27, wherein the concentration of the sphering surfactant ranges from about 5 up to about 1,000 mg/L.

### Claim 34 (depends on 27)

The method according to claim 27, wherein the osmolality adjustment component is sodium chloride, potassium chloride or a mixture thereof.

### Claim 35 (depends on 27)

The method according to claim 27, wherein the concentration of the osmolality adjustment component ranges from about 0.25% up to about 25%.

### Claim 36 (depends on 27)

The method according to claim 27, wherein the reagent further comprises an antimicrobial agent.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the concentration of the antimicrobial agent ranges from about 0.02% up to about 0.1%.

### Claim 38 (depends on 27)

The method according to claim 27, wherein the pH of the reagent ranges from about 6.0 up to about 8.0 pH units.

### Claim 39 (depends on 27)

The method according to claim 27, wherein the osmolality of a 1× concentration solution of the reagent ranges from about 250 up to about 350 mOsm.
